Court restricts abortion access across US by blocking mailing of mifepristone

abcnews - A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone

AI Summary: A federal appeals court has imposed new limits on distribution of mifepristone, blocking mail-order shipments and narrowing telehealth-based prescribing. The decision immediately complicates access for patients and clinicians who rely on remote care and pharmacy delivery, forcing last‑minute logistical changes, increased travel, and swift legal and policy responses as providers scramble to adapt.


Appeals court halts mail and telehealth access

2 months / abcnews


Clinical pivots and drug alternatives amid disruptions

2 months / abcnews


Supreme Court temporarily restores mail access

2 months / medicalxpress

2 months / fiercehealthcare


All Other Stories

2 months / npr / Ryan Benk


Back to Top / Sat, May 2, 2026, 7:21 am / permalink 23121 / 14 stories in 2 months /




Related Stories


FDA updates mifepristone safety review, but pharmacies remain reluctant / 2 months

Telehealth abortion pills rise as teens drive online demand / 3 months

Supreme Court preserves telehealth and mail access to abortion pill / 1 month

FDA weighs easing access to compounded peptides for patients / 2 months

Abortion‑pill bans won’t stop telehealth access, providers say / 14 days

New women's health plan draws criticism for ignoring women's voices / 2 months

FDA to Remove Black Box Warnings from Menopausal Hormone Therapies / 7 months

StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Infectious Disease, Medicare Advantage (not listed), Infant Health, Clinical Trials and look for the RSS link.





NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.